Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25429782 | 1.00 | HPGD (0.38) | HPGDHCAR3HCAR2LMNAGRM2 | |
| SCHEMBL18510383 | 0.76 | KDM4E (0.38) | HPGDHCAR3HCAR2LMNAGRM2 | |
| SCHEMBL31339732 | 0.74 | HPGD (0.37) | HPGDHCAR3HCAR2LMNAGRM2 | |
| SCHEMBL25429938 | 0.74 | HPGD (0.37) | HPGDHCAR3HCAR2LMNAGRM2 | |
| SCHEMBL31339740 | 0.73 | GRM2 (0.57) | HCAR3GRM2 | |
| SCHEMBL25429341 | 0.73 | GRM2 (0.57) | HCAR3GRM2 | |
| SCHEMBL18521198 | 0.71 | ADORA2A (0.41) | HPGDHCAR3HCAR2LMNASMN1; SMN2 | |
| SCHEMBL7091031 | 0.70 | SMN1; SMN2 (0.46) | HCAR3ALDH1A1SMN1; SMN2 | |
| SCHEMBL3475847 | 0.70 | GRM2 (0.39) | GRM2 | |
| SCHEMBL8513025 | 0.68 | GRM2 (0.31) | HPGDHCAR3HCAR2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SHENZHEN YUANLI SHENWAN INNOVATIVE MEDICINE CO LTD (CN) | 2025-04-17 | — | — | US | disclosed |
| CN-119365192-A | Heteroaryl compounds as HPK1 inhibitors and methods of use thereof | 深圳市原力深湾创新药有限公司 | 2025-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122174-A1 | Heteroaryl Compounds As HPK1 Inhibitors And Methods Of Using Same | SGK1, HYPK, PCK1 | HPGD 418/4885HCAR3 253/4885HCAR2 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.